Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 29 Oct 2026
Standard addition

Comparing SGLT2 Inhibitors on Incident Major Adverse Kidney Events in Type 2 Diabetes: A Target Trial Emulation

Two of three SGLT2 inhibitors showed modest but measurable protection against serious kidney complications in type 2 diabetes.

This target-trial emulation using weighted retrospective claims cohorts examined Comparing SGLT2 Inhibitors on Incident Major Adverse Kidney Events in Type 2 Diabetes: A Target Trial Emulation. Dapagliflozin and empagliflozin were associated with modestly fewer major adverse kidney events than canagliflozin.

What the study was

Study design
Target-trial emulation using weighted retrospective claims cohorts
Population
Adults with type 2 diabetes at moderate cardiovascular risk without stage 3 or worse chronic kidney disease
Sample size
131,434 weighted initiators
Category
Treatment Innovation
Maturity
Validated
Journal
Mayo Clinic proceedings

Why it surfaced

Target-trial emulation using weighted retrospective claims cohorts; Dapagliflozin and empagliflozin were associated with modestly fewer major adverse kidney events than canagliflozin. Score kept conservative because only the PubMed abstract and metadata were reviewed.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.